A method for nucleic acid detection using an optimized single-stranded nucleic acid detector

By using a single-stranded nucleic acid detector with any 21-29 bases to bind to CRISPR/CAS effector protein, the problem of insufficient detection efficiency and accuracy in the prior art is solved, and more efficient target nucleic acid detection is achieved, and detection is improved. Sensitivity and accuracy.

CN114517224BActive Publication Date: 2024-11-05SHANDONG SHUNFENG BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202011295714.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-11-18
Publication Date
2024-11-05
Estimated Expiration
2040-11-18

AI Technical Summary

Technical Problem

The existing CRISPR-based nucleic acid detection technology has shortcomings in terms of sensitivity and accuracy, especially in target nucleic acid detection, the probe design is limited, which affects the detection efficiency.

Method used

A single-stranded nucleic acid detector containing any 21-29 bases is used to bind V-type CRISPR/CAS effector protein and gRNA, and a detectable signal is generated by cleavage single-stranded nucleic acid detector such as Cas12i or Cas12j to improve the detection signal. Test efficiency and accuracy.

Benefits of technology

It significantly improves the sensitivity and accuracy of target nucleic acid detection, enhances detection efficiency, and can cut single-stranded nucleic acid detectors more efficiently to generate reliable detection signals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114517224B_ABST
    Figure CN114517224B_ABST
Patent Text Reader

Abstract

The present invention provides a method for detecting a target nucleic acid in a sample, the method comprising contacting the sample with a V-type CRISPR / CAS effector protein, a gRNA (guide RNA) and a single-stranded nucleic acid detector, detecting a detectable signal generated by the CRISPR / CAS effector protein cleaving the single-stranded nucleic acid detector, thereby detecting the target nucleic acid; specifically, the single-stranded nucleic acid detector contains 21-29 arbitrary bases, preferably 21-25 arbitrary bases, preferably 25 arbitrary bases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of nucleic acid detection, and more particularly to a method, system and kit for detecting target nucleic acid using a single-stranded nucleic acid detector containing 21 to 29 arbitrary bases. Background Art

[0002] Specific detection methods of nucleic acid molecules have important application value, such as pathogen detection, genetic disease detection, etc. In terms of pathogen detection, since each pathogen microorganism has its own unique characteristic nucleic acid molecule sequence, it is possible to develop nucleic acid molecule detection for specific species, also known as nucleic acid diagnostics (NADs, nucleic acid diagnostics), which is of great significance in the fields of food safety, environmental microbial pollution detection, human pathogen infection, etc. Another aspect is the detection of single nucleotide polymorphisms (SNPs, singlenucleotide polymorphisms) in humans or other species. Understanding the relationship between genetic variation and biological function at the genome level provides a new perspective for modern molecular biology, and SNPs are closely related to biological functions, evolution and diseases, so the development of SNPs detection and analysis technology is particularly important.

[0003] The currently established specific nucleic acid molecule detection usually needs to be divided into two steps. The first step is the amplification of the target nucleic acid, and the second step is the detection of the target nucleic acid. Existing detection technologies include restriction endonuclease method, Southern, Northern, dot hybridization, fluorescent PCR detection technology, LAMP loop-mediated isothermal amplification technology, recombinase polymerase amplification technology (RPA) and other methods. After 2012, CRISPR gene editing technology emerged. Zhang Feng's team developed a new nucleic acid diagnostic technology (SHERLOCK technology) targeting RNA with Cas13 as the core based on RPA technology. Doudna's team developed a diagnostic technology (DETECTR technology) with Cas12 enzyme as the core. Dr. Wang Jin and others from the Shanghai Institute of Plant Physiology and Ecology of the Chinese Academy of Sciences also developed a new nucleic acid detection technology based on Cas12 (HOLMES technology). Nucleic acid detection technology developed based on CRISPR technology is playing an increasingly important role.

[0004] In CRISPR-based nucleic acid detection technology, nucleic acid probes or nucleic acid detectors are key components of the above detection technology. The present invention improves the nucleic acid probe and selects a single-stranded nucleic acid detector containing 21-29 arbitrary bases as the probe, thereby improving the detection efficiency of the technology, specifically improving the sensitivity, accuracy and precision. Summary of the invention

[0005] The present invention provides a method, a system and a kit for detecting a target nucleic acid using a single-stranded nucleic acid detector containing 21 to 29 arbitrary bases.

[0006] method

[0007] On the one hand, the present invention provides a method for detecting a target nucleic acid in a sample, the method comprising contacting the sample with a V-type CRISPR / CAS effector protein, a gRNA (guide RNA) and a single-stranded nucleic acid detector, the gRNA comprising a region binding to the CRISPR / CAS effector protein and a guide sequence hybridizing with the target nucleic acid; detecting a detectable signal generated by the CRISPR / CAS effector protein cutting the single-stranded nucleic acid detector, thereby detecting the target nucleic acid.

[0008] On the other hand, a method for cutting a single-stranded nucleic acid detector is characterized in that the method includes contacting the single-stranded nucleic acid detector with a target nucleic acid, a V-type CRISPR / CAS effector protein and a gRNA (guide RNA), the gRNA including a region that binds to the CRISPR / CAS effector protein and a guide sequence that hybridizes with the target nucleic acid, and the V-type CRISPR / CAS effector protein is selected from one or a combination of Cas12i, Cas12j.

[0009] After the V-type CRISPR / CAS effector protein contacts the gRNA and the target nucleic acid, the trans activity is stimulated, and the single-stranded nucleic acid detector of the present invention can be cut more efficiently, reflecting a detectable signal.

[0010] Composition

[0011] On the other hand, the present invention provides a composition for detecting a target nucleic acid in a sample, the composition comprising a V-type CRISPR / CAS effector protein, a gRNA (guide RNA) and a single-stranded nucleic acid detector. The sample is contacted with the composition, and a detectable signal generated by the CRISPR / CAS effector protein cleaving the single-stranded nucleic acid detector is detected, thereby detecting the target nucleic acid.

[0012] Reagent test kit

[0013] On the other hand, the present invention provides a kit for detecting a target nucleic acid in a sample, the kit comprising a V-type CRISPR / CAS effector protein, a gRNA (guide RNA) and a single-stranded nucleic acid detector. The sample is contacted with each component in the kit, and a detectable signal generated by the CRISPR / CAS effector protein cutting the single-stranded nucleic acid detector is detected, thereby detecting the target nucleic acid.

[0014] In one embodiment, the kit also provides containers required for the reaction.

[0015] In one embodiment, the kit also provides reagents and instruments required for extracting target nucleic acid (DNA).

[0016] In one embodiment, the kit further comprises a standard for verifying the detection results of the kit.

[0017] Single-stranded nucleic acid detector

[0018] In one embodiment, the single-stranded nucleic acid detector does not hybridize to the gRNA.

[0019] In one embodiment, the single-stranded nucleic acid detector contains 21-29 arbitrary bases, specifically 21, 22, 23, 24, 25, 26, 27, 28 or 29 arbitrary bases, preferably 21-25 arbitrary bases, preferably 25 arbitrary bases.

[0020] In one embodiment, the A+T content of the single-stranded nucleic acid detector is 10%-100%, specifically, 10%-20%, 20%-25%, 25%-30%, 30%-40%, 40%-50%, 50%-60%, 60%-70%, 70%-80%, 80%-100%.

[0021] In one embodiment, the base refers to the nitrogenous base (base) at the 1st position of ribose or deoxyribose.

[0022] The bases include one or more of adenine A, uracil U, cytosine C, guanine G, thymine T, hypoxanthine I, adenine A modifiers, uracil U modifiers, cytosine C modifiers, guanine G modifiers, thymine T modifiers, and hypoxanthine I modifiers.

[0023] The modified bases are obtained by chemically modifying adenine A, uracil U, cytosine C, guanine G, thymine T, and hypoxanthine I in nucleotides. People familiar with this process can easily understand other similar base modifications, so these other methods should also fall within the scope of the present invention.

[0024] In one embodiment, the single-stranded nucleic acid detector also includes an abasic spacer (the single-stranded nucleic acid detector including an abasic spacer is also recorded in the Chinese application CN2020106946328); the abasic spacer is selected from one or any several of dSpacer, Spacer C3, Spacer C6, Spacer C12, Spacer9, Spacer12, Spacer18, InvertedAbasic Site (dSpacerabasic furan) and rAbasic Site (rSpacerabasic furan).

[0025] The single-stranded nucleic acid detector may be linear or circular.

[0026] In some embodiments, different reporter groups are respectively set at the 5' end and the 3' end of the single-stranded nucleic acid detector, and when the single-stranded nucleic acid detector is cut, a detectable reporter signal can be exhibited; for example, a fluorescent group and a quenching group are respectively set at both ends of the single-stranded nucleic acid detector; or a first molecule (such as FAM or FITC) and a second molecule (such as biotin) connected to the 3' end are respectively set at both ends of the single-stranded nucleic acid detector.

[0027] When a fluorescent group and a quenching group are respectively arranged at both ends of the single-stranded nucleic acid detector, a detectable fluorescent signal can be exhibited after the single-stranded nucleic acid detector is cut.

[0028] When the first molecule (such as FAM or FITC) and the second molecule (such as biotin) are respectively arranged at both ends of the single-stranded nucleic acid detector, the reaction system containing the single-stranded nucleic acid detector cooperates with the flow strip to detect the characteristic sequence (preferably, colloidal gold detection method). The flow strip is designed to have two capture lines, and an antibody that binds to the first molecule (i.e., the first molecule antibody) is provided at the sample contact end (colloidal gold), and an antibody that binds to the first molecule antibody is contained at the first line (control line), and an antibody that binds to the second molecule antibody (i.e., the second molecule antibody, such as avidin) is contained at the second line (test line). When the reaction flows along the strip, the first molecule antibody binds to the first molecule and carries the cut or uncut oligonucleotide to the capture line, and the cut reporter will bind to the antibody of the first molecule antibody at the first capture line, and the uncut reporter will bind to the second molecule antibody at the second capture line. The binding of the reporter group to each line will result in a strong readout / signal (e.g., color). As more reporters are cut, more signals will accumulate at the first capture line, and less signals will appear at the second line.

[0029] In one embodiment, the fluorescent group is selected from one or any several of FAM, FITC, VIC, JOE, TET, CY3, CY5, ROX, Texas Red or LC RED460; the quenching group is selected from one or any several of BHQ1, BHQ2, BHQ3, Dabcy1, cy3, cy5 or Tamra.

[0030] CRISPR / Cas effector proteins

[0031] Furthermore, the V-type CRISPR / CAS effector protein is selected from Cas12 family proteins or mutants thereof.

[0032] In one embodiment, the Cas protein is preferably a Cas12 family, including but not limited to one or any several of Cas12a, Cas12b, Cas12d, Cas12e, Cas12f, Cas12g, Cas12h, Cas12i, and Cas12j.

[0033] In one embodiment, the Cas12a is selected from one or any several of FnCas12a, AsCas12a, LbCas12a, Lb5Cas12a, HkCas12a, OsCas12a, TsCas12a, BbCas12a, BoCas12a or Lb4Cas12a; the Cas12a is preferably LbCas12a, and the amino acid sequence is as shown in SEQ ID No.3, or the amino acid sequence shown in SEQ ID No.3 or its active fragment is substituted, deleted or added with one or more (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid residues, and has a derivative protein with substantially the same function.

[0034] In other embodiments, the amino acid sequence of Cas12b is as shown in SEQ ID No.4, or the amino acid sequence shown in SEQ ID No.4 or its active fragment is formed by replacing, deleting or adding one or more (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid residues, and a derivative protein having substantially the same function.

[0035] In a preferred embodiment, the amino acid sequence of the Cas12i protein is selected from the group consisting of:

[0036] (1) the protein shown in SEQ ID No. 1;

[0037] (2) A derivative protein having substantially the same function as the amino acid sequence shown in SEQ ID No. 1 or its active fragment formed by substitution, deletion or addition of one or more (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid residues.

[0038] In a preferred embodiment, the amino acid sequence of the Cas12j protein is selected from the group consisting of:

[0039] (1) the protein shown in SEQ ID No. 2;

[0040] (2) A derivative protein having substantially the same function as the amino acid sequence shown in SEQ ID No. 2 or its active fragment formed by substitution, deletion or addition of one or more (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid residues.

[0041] In one embodiment, the Cas protein mutant comprises an amino acid substitution, deletion or replacement, and the mutant at least retains its trans cleavage activity. Preferably, the mutant has Cis and trans cleavage activity.

[0042] Target nucleic acid

[0043] In the present invention, the target nucleic acid includes ribonucleotides or deoxyribonucleotides, including single-stranded nucleic acids, double-stranded nucleic acids, such as single-stranded DNA, double-stranded DNA, single-stranded RNA, double-stranded RNA, DNA-RNA hybrids, or nucleic acid modifications.

[0044] In one embodiment, the target nucleic acid is derived from samples such as viruses, bacteria, microorganisms, soil, water, human body, animals, plants, etc.

[0045] In one embodiment, the target nucleic acid is a product enriched or amplified by methods such as PCR, NASBA, RPA, SDA, LAMP, HAD, NEAR, MDA, RCA, LCR, RAM, etc.

[0046] In one embodiment, the method further comprises the step of obtaining the target nucleic acid from the sample.

[0047] In one embodiment, the target nucleic acid is a viral nucleic acid, a bacterial nucleic acid, a specific nucleic acid associated with a disease, such as a specific mutation site or a SNP site or a nucleic acid that differs from a control; preferably, the virus is a plant virus or an animal virus, for example, a papillomavirus, a hepadnavirus, a herpes virus, an adenovirus, a poxvirus, a parvovirus, a coronavirus; preferably, the virus is a coronavirus, preferably, SARS, SARS-CoV2 (COVID-19), HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, Mers-Cov.

[0048] In some embodiments, the target nucleic acid is derived from cells, for example, from cell lysate.

[0049] Detectable signal

[0050] In some embodiments, the method of the present invention further comprises the step of measuring a detectable signal generated by a CRISPR / CAS effector protein (Cas protein). After the V-type CRISPR / CAS effector protein contacts the gRNA and the target nucleic acid, the trans activity is stimulated, and the single-stranded nucleic acid detector of the present invention can be cut more efficiently, reflecting a detectable signal.

[0051] In the present invention, the detectable signal can be any signal generated when the single-stranded nucleic acid detector is cut, for example, detection based on gold nanoparticles, fluorescence polarization, fluorescence signal, colloidal phase transition / dispersion, electrochemical detection, and semiconductor-based sensing.

[0052] The detectable signal can be read by any suitable means, including but not limited to: measurement of a detectable fluorescent signal, gel electrophoresis detection (by detecting changes in bands on the gel), visual or sensor-based detection of the presence or absence of a color, or a difference in the presence of a color (e.g., based on gold nanoparticles) and a difference in an electrical signal.

[0053] In some embodiments, the measurement of the detectable signal can be quantitative, and in other embodiments, the measurement of the detectable signal can be qualitative.

[0054] Proportion

[0055] In one embodiment, the molar ratio of the Cas protein to the gRNA is (0.8-1.2):1.

[0056] In one embodiment, the final concentration of the Cas protein is 20-200 nM, preferably, 30-100 nM, more preferably, 40-80 nM, more preferably, 50 nM.

[0057] In one embodiment, the final concentration of the gRNA is 20-200 nM, preferably, 30-100 nM, more preferably, 40-80 nM, more preferably, 50 nM.

[0058] In one embodiment, the target nucleic acid is used at a final concentration of 5-100 nM, preferably, 10-50 nM.

[0059] In one embodiment, the single-stranded nucleic acid detector is used at a final concentration of 100-1000 nM, preferably 150-800 nM, preferably 200-800 nM, preferably 200-500 nM, preferably 200-300 nM.

[0060] use

[0061] On the other hand, the present invention also provides use of the above-mentioned single-stranded nucleic acid detector in preparing a composition, a reagent or a kit for detecting a target nucleic acid in a sample.

[0062] In one embodiment, the above-mentioned composition, reagent or kit also includes a V-type CRISPR / CAS effector protein and a gRNA (guide RNA), the gRNA including a region that binds to the CRISPR / CAS effector protein and a guide sequence that hybridizes with the target nucleic acid, and the V-type CRISPR / CAS effector protein is selected from one or a combination of Cas12i, Cas12j.

[0063] On the other hand, the present invention also provides a use of the above-mentioned single-stranded nucleic acid detector in improving the detection efficiency of a nucleic acid detection composition, a nucleic acid detection reagent or a nucleic acid detection kit.

[0064] On the other hand, the present invention also provides the use of the above composition, reagent or kit in detecting target nucleic acid in a sample.

[0065] General Definition:

[0066] Unless defined otherwise, technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0067] The term "hybridization" or "complementary" or "substantially complementary" refers to a nucleic acid (e.g., RNA, DNA) comprising a nucleotide sequence that enables it to non-covalently bind, i.e., to form base pairs and / or G / U base pairs, "anneal" or "hybridize" with another nucleic acid in a sequence-specific, antiparallel manner (i.e., nucleic acid-specific binding to complementary nucleic acids). Hybridization requires that the two nucleic acids contain complementary sequences, although there may be mismatches between the bases. Suitable conditions for hybridization between two nucleic acids depend on the length of the nucleic acids and the degree of complementarity, which are variables well known in the art. Typically, the length of a hybridizable nucleic acid is 8 nucleotides or more (e.g., 10 nucleotides or more, 12 nucleotides or more, 15 nucleotides or more, 20 nucleotides or more, 22 nucleotides or more, 25 nucleotides or more, or 30 nucleotides or more).

[0068] It should be understood that the sequence of a polynucleotide need not be 100% complementary to the sequence of its target nucleic acid to specifically hybridize. A polynucleotide may comprise 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence complementarity to the target region in the target nucleic acid sequence with which it hybridizes.

[0069] The term "amino acid" refers to a carboxylic acid containing an amino group. Various proteins in living organisms are composed of 20 basic amino acids.

[0070] The terms "polynucleotide", "nucleotide sequence", "nucleic acid sequence", "nucleic acid molecule" and "nucleic acid" are used interchangeably and include DNA, RNA or hybrids thereof, which may be double-stranded or single-stranded.

[0071] The terms "homology" or "identity" are used to refer to the matching of sequences between two polypeptides or between two nucleic acids. When a position in the two sequences being compared is occupied by the same base or amino acid monomer subunit (e.g., a position in each of the two DNA molecules is occupied by adenine, or a position in each of the two polypeptides is occupied by lysine), then the molecules are identical at that position. Between the two sequences. Typically, the comparison is made when the two sequences are aligned to produce maximum identity. Such comparison can be by using, for example, the identity of amino acid sequence can be by conventional methods, reference such as Smith and Waterman, 1981, Adv.Appl.Math.2:482 Pearson Lipman, 1988, Proc.Natl.Acad.Sci.USA 85:2444, Thompson et al., 1994, Nucleic Acids Res 22:467 380 etc., by computerized operation algorithm (GAP in Wisconsin Genetics software package, BESTFIT, FASTA, and TFASTA, Genetics Computer Group) determine. Also can use the BLAST algorithm that can be obtained from the National Center for Biotechnology Information (NCBI www.ncbi.nlm.nih.gov / ), use default parameters to determine.

[0072] As used herein, "biotin", also known as vitamin H, is a small molecule vitamin with a molecular weight of 244 Da. "Avidin", also known as anti-biotin, is an alkaline glycoprotein with 4 binding sites with extremely high affinity to biotin. Commonly used avidins include streptavidin. The extremely strong affinity of biotin and avidin can be used to amplify or enhance the detection signal in the detection system. For example, biotin can easily bind to proteins (such as antibodies, etc.) with covalent bonds, and the avidin molecules bound to the enzyme react with the biotin molecules bound to the specific antibody, which not only plays a multi-stage amplification role, but also produces color due to the catalytic effect of the enzyme when it encounters the corresponding substrate, thereby achieving the purpose of detecting unknown antigen (or antibody) molecules.

[0073] Single-stranded nucleic acid detector

[0074] The single-stranded nucleic acid detector described in the present invention is used in a detection method or system to report whether a characteristic sequence is contained. The single-stranded nucleic acid detector includes different reporting groups or labeling molecules at both ends. When it is in the initial state (i.e., uncleaved state), it does not present a reporting signal. When the single-stranded nucleic acid detector is cleaved, it presents a detectable signal, i.e., a detectable difference is shown after cleavage and before cleavage. In the present invention, if a detectable difference can be detected, it reflects that the target nucleic acid contains the characteristic sequence to be detected; alternatively, if the detectable difference cannot be detected, it reflects that the target nucleic acid does not contain the characteristic sequence to be detected.

[0075] In one embodiment, the reporter group or labeling molecule includes a fluorescent group and a quencher group, the fluorescent group is selected from one or any several of FAM, FITC, VIC, JOE, TET, CY3, CY5, ROX, Texas Red or LC RED460; the quencher group is selected from one or any several of BHQ1, BHQ2, BHQ3, Dabcy1 or Tamra.

[0076] In one embodiment, the single-stranded nucleic acid detector has a first molecule (such as FAM or FITC) connected to the 5' end and a second molecule (such as biotin) connected to the 3' end. The reaction system containing the single-stranded nucleic acid detector is used to detect the characteristic sequence in conjunction with the flow strip (preferably, colloidal gold detection method). The flow strip is designed to have two capture lines, with an antibody that binds to the first molecule (i.e., the first molecule antibody) at the sample contact end (colloidal gold), an antibody that binds to the first molecule antibody at the first line (control line), and an antibody that binds to the second molecule antibody (i.e., the second molecule antibody, such as avidin) at the second line (test line). When the reaction flows along the strip, the first molecule antibody binds to the first molecule and carries the cut or uncut oligonucleotide to the capture line, and the cut reporter will bind to the antibody of the first molecule antibody at the first capture line, and the uncut reporter will bind to the second molecule antibody at the second capture line. The binding of the reporter group to each line will result in a strong readout / signal (e.g., color). As more reporters are cut, more signals will accumulate at the first capture line, and less signals will appear at the second line.

[0077] The detection method of the present invention can be used for quantitative detection of characteristic sequences to be detected. The quantitative detection index can be quantified according to the signal strength of the reporter group, such as according to the luminescence intensity of the fluorescent group, or according to the width of the color band.

[0078] Abasic spacer

[0079] As used herein, "abasic spacer" refers to a nucleoside that does not contain specific coding information. Abasic spacers can be bound to oligonucleotides, including the 3' and 5' ends, or inside the nucleotide chain. Common Spacers include: dSpacer (abasic furan), Spacer C3, Spacer C6, Spacer C12, Spacer9, Spacer12, Spacer18, Inverted Abasic Site (dSpacerabasic furan) and rAbasic Site (rSpacerabasic furan).

[0080] The above-mentioned abasic spacer is abasic spacer well known in the art. For example, dSpacer, Spacer 9, Spacer 18, and Spacer C3 are disclosed in US Pat. No. 8,153,772B2; and dSpacer is disclosed in Chinese patent application CN101454451A.

[0081] The preferred abasic spacer "dSpacer" herein is also called an abasic site, tetrahydrofuran (THF) or apurinic / apyrimidinic (AP) site, or an abasic linker, in which the methylene group is located at the 1 position of the 2'-deoxyribose. dSpacer is not only very similar to the natural site in structure, but also quite stable. The structure is shown below:

[0082]

[0083] When the dSpacer is linked to a nucleotide, it can form the following structure:

[0084]

[0085] Target nucleic acid

[0086] As used herein, the "target nucleic acid" refers to a polynucleotide molecule extracted from a biological sample (sample to be tested). The biological sample is any solid or fluid sample obtained, excreted or secreted from any organism, including but not limited to single-cell organisms, such as bacteria, yeast, protozoa and amoeba, etc., multicellular organisms (such as plants or animals, including samples from healthy or apparently healthy human subjects or human patients affected by the disease or disease to be diagnosed or investigated, such as pathogenic microorganisms such as infection of pathogenic bacteria or viruses). For example, a biological sample can be a biological fluid obtained from, for example, blood, plasma, serum, urine, feces, sputum, mucus, lymph, synovial fluid, bile, ascites, pleural effusion, seroma, saliva, cerebrospinal fluid, aqueous or vitreous humor, or any body secretion, exudate, exudate (e.g., liquid obtained from an abscess or any other infection or inflammation site) or a liquid obtained from a joint (e.g., a normal joint or a joint affected by a disease, such as rheumatoid arthritis, osteoarthritis, gout or septic arthritis), or a swab of the skin or mucosal surface. The sample can also be a sample obtained from any organ or tissue (including biopsy or autopsy specimens, such as tumor biopsies) or can contain cells (primary cells or cultured cells) or culture medium conditioned by any cells, tissues or organs. Exemplary samples include, but are not limited to, cells, cell lysates, blood smears, cell centrifugation preparations, cytological smears, body fluids (e.g., blood, plasma, serum, saliva, sputum, urine, bronchoalveolar lavage, semen, etc.), tissue biopsies (e.g., tumor biopsies), fine needle aspirates, and / or tissue sections (e.g., cryostat tissue sections and / or paraffin-embedded tissue sections).

[0087] In other embodiments, the biological sample can be plant cells, calli, tissues or organs (such as roots, stems, leaves, flowers, seeds, fruits), etc.

[0088] In the present invention, the target nucleic acid also includes a DNA molecule formed by reverse transcription RNA. Further, the target nucleic acid can be amplified using techniques known in the art, and the amplification techniques include isothermal amplification techniques and non-isothermal amplification techniques. Isothermal amplification can be based on nucleic acid sequencing amplification (NASBA), recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), helicase-dependent amplification (HDA), or nickase amplification reaction (NEAR). In certain exemplary embodiments, non-isothermal amplification methods can be used, including but not limited to PCR, multiple displacement amplification (MDA), rolling circle amplification (RCA), ligase chain reaction (LCR), or derivative amplification method (RAM).

[0089] Furthermore, the detection method of the present invention further comprises a step of amplifying the target nucleic acid; the detection system further comprises a reagent for amplifying the target nucleic acid. The amplification reagent comprises one or more of the following groups: DNA polymerase, strand displacement enzyme, helicase, recombinase, single-stranded binding protein, etc.

[0090] CRISPR

[0091] As used herein, the "CRISPR" refers to Clustered regularly interspaced short palindromic repeats, which are derived from the immune system of microorganisms.

[0092] Cas proteins

[0093] The "Cas protein" described herein refers to a CRISPR-associated protein, preferably a type V or type VI CRISPR / CAS protein (CRISPR / CAS effector protein), which, once bound to a characteristic sequence (target sequence) to be detected (i.e., forming a ternary complex of Cas protein-gRNA-target sequence), can induce its trans activity, i.e., randomly cut non-targeted single-stranded nucleotides (i.e., the single-stranded nucleic acid detector described herein). When the Cas protein binds to the characteristic sequence, it can induce its trans activity by cutting or not cutting the characteristic sequence; preferably, it induces its trans activity by cutting the characteristic sequence; more preferably, it induces its trans activity by cutting the single-stranded characteristic sequence. The Cas protein recognizes the characteristic sequence by recognizing the PAM (protospacer adjacent motif) adjacent to the characteristic sequence.

[0094] The Cas protein described in the present invention is a protein having at least trans cleavage activity, preferably, the Cas protein is a protein having Cis and trans cleavage activity. The Cis activity refers to the activity of the Cas protein in recognizing the PAM site and specifically cleaving the target sequence under the action of gRNA.

[0095] The Cas protein described in the present invention includes a V-type CRISPR / CAS effector protein, including a protein family such as Cas12 and Cas14. Preferably, for example, Cas12 protein, such as Cas12a, Cas1 2b, Cas12i, Cas12j; preferably, the Cas protein is Cas12a, Cas12b, Cas12i, Cas12j; the Cas14 protein family includes Cas14a, Cas14b, etc.

[0096] In an embodiment, the Cas protein referred to herein, such as Cas12, also encompasses functional variants of Cas or its homologs or orthologs. As used herein, the "functional variant" of a protein refers to a variant of such a protein that at least partially retains the activity of the protein. Functional variants may include mutants (which may be insertion, deletion or substitution mutants), including polymorphs, etc. Functional variants also include fusion products of such a protein with another generally unrelated nucleic acid, protein, polypeptide or peptide. Functional variants may be naturally occurring or may be artificial. Favorable embodiments may relate to engineered or non-naturally occurring V-type DNA targeting effector proteins.

[0097] In one embodiment, one or more nucleic acid molecules encoding a Cas protein, such as Cas12, or its orthologs or homologs can be codon optimized for expression in eukaryotic cells. Eukaryotic organisms can be as described herein. One or more nucleic acid molecules can be engineered or non-naturally occurring.

[0098] In one embodiment, the Cas12 protein or its ortholog or homolog may comprise one or more mutations (and thus the nucleic acid molecule encoding it may have one or more mutations. The mutation may be an artificially introduced mutation and may include, but is not limited to, one or more mutations in the catalytic domain.

[0099] In one embodiment, the Cas protein can be from: Leptotrichia, Listeria, Corynebacterium, Sutterella, Legionella, Treponema, Mycobacterium, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Azospirillum, Sphaerochaeta, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, Campylobacter, and Lachnospira.

[0100] In one embodiment, the Cas protein is selected from the group consisting of the following sequences:

[0101] (1) Proteins shown in SEQ ID No. 1-4;

[0102] (2) A derivative protein having substantially the same function as the amino acid sequence shown in SEQ ID No. 1-4 or its active fragment sequence formed by substitution, deletion or addition of one or more (such as 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid residues.

[0103] In one embodiment, the Cas protein also includes a protein having 50%, preferably 55%, preferably 60%, preferably 65%, preferably 70%, preferably 75%, preferably 80%, preferably 85%, preferably 90%, preferably 95% sequence identity (homology) with the above sequence and having trans activity.

[0104] The Cas protein can be obtained by recombinant expression vector technology, that is, the nucleic acid molecule encoding the protein is constructed into a suitable vector, and then transformed into a host cell, so that the encoding nucleic acid molecule is expressed in the cell, thereby obtaining the corresponding protein. The protein can be secreted by the cell, or the cell can be cracked to obtain the protein by conventional extraction techniques. The encoding nucleic acid molecule can be integrated into the genome of the host cell for expression, or it can be expressed without being integrated into the host cell. The vector further includes regulatory elements that are conducive to sequence integration or self-replication. The vector can be, for example, a plasmid, a virus, a cosmid, a phage, etc., which are well known to those skilled in the art. Preferably, the expression vector in the present invention is a plasmid. The vector further includes one or more regulatory elements selected from promoters, enhancers, ribosome binding sites for translation initiation, terminators, polyadenylic acid sequences, and selection marker genes.

[0105] The host cell can be a prokaryotic cell, such as Escherichia coli, Streptomyces, Agrobacterium; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a plant cell. Those skilled in the art are aware of how to select appropriate vectors and host cells.

[0106] gRNA

[0107] As used herein, the "gRNA" is also referred to as guide RNA or guide RNA, and has the meaning generally understood by those skilled in the art. In general, the guide RNA may include a direct repeat sequence and a guide sequence, or may consist essentially of or consist of a direct repeat sequence and a guide sequence (also referred to as a spacer in the context of an endogenous CRISPR system). In different CRISPR systems, gRNA may include crRNA and tracrRNA, or may only contain crRNA, depending on the different Cas proteins on which it depends. CrRNA and tracrRNA may be artificially modified and fused to form a single guide RNA (sgRNA). In some cases, the guide sequence is any polynucleotide sequence that has sufficient complementarity with the target sequence (the characteristic sequence described in the present invention) to hybridize with the target sequence and guide the specific binding of the CRISPR / Cas complex to the target sequence, typically having a sequence length of 12-25nt. The direct repeat sequence may be folded to form a specific structure (such as a stem-loop structure) for recognition by the Cas protein to form a complex. The guide sequence does not need to be 100% complementary to the characteristic sequence (target sequence). The guide sequence is not complementary to the single-stranded nucleic acid detector.

[0108] In certain embodiments, when optimally aligned, the degree of complementarity (match) between a guide sequence and its corresponding target sequence is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%. Determining optimal alignment is within the capabilities of one of ordinary skill in the art. For example, there are publicly available and commercially available alignment algorithms and programs, such as, but not limited to, ClustalW, Smith-Waterman in matlab, Bowtie, Geneious, Biopython, and SeqMan.

[0109] The gRNA described in the present invention may be natural, or artificially modified or designed and synthesized.

[0110] Sequence information

[0111]

[0112] SEQUENCE LISTING <110> Shandong Shunfeng Biotechnology Co., Ltd. <120> A method for nucleic acid detection using an optimized single-stranded nucleic acid detector <130> JH-CNP201842DJ <160> 9 <170> PatentIn version 3.5 <210> 1 <211> 1045 <212> PRT <213> Artificial Sequence <220> <223> Cas12i <400> 1 Met Lys Lys Val Glu Val Ser Arg Pro Tyr Gln Ser Leu Leu Leu Pro 1 5 10 15 Asn His Arg Lys Phe Lys Tyr Leu Asp Glu Thr Trp Asn Ala Tyr Lys 20 25 30 Ser Val Lys Ser Leu Leu His Arg Phe Leu Val Cys Ala Tyr Gly Ala 35 40 45 Val Pro Phe Asn Lys Phe Val Glu Val Val Glu Lys Val Asp Asn Asp 50 55 60 Gln Leu Val Leu Ala Phe Ala Val Arg Leu Phe Arg Leu Val Pro Val 65 70 75 80 Glu Ser Thr Ser Phe Ala Lys Val Asp Lys Ala Asn Leu Ala Lys Ser 85 90 95 Leu Ala Asn His Leu Pro Val Gly Thr Ala Ile Pro Ala Asn Val Gln 100 105 110 Ser Tyr Phe Asp Ser Asn Phe Asp Pro Lys Lys Tyr Met Trp Ile Asp 115 120 125 Cys Ala Trp Glu Ala Asp Arg Leu Ala Arg Glu Met Gly Leu Ser Ala 130 135 140 Ser Gln Phe Ser Glu Tyr Ala Thr Thr Met Leu Trp Glu Asp Trp Leu 145 150 155 160 Pro Leu Asn Lys Asp Asp Val Asn Gly Trp Gly Ser Val Ser Gly Leu 165 170 175 Phe Gly Glu Gly Lys Lys Glu Asp Arg Gln Gln Lys Val Lys Met Leu 180 185 190 Asn Asn Leu Leu Asn Gly Ile Lys Lys Asn Pro Pro Lys Asp Tyr Thr 195 200 205 Gln Tyr Leu Lys Ile Leu Leu Asn Ala Phe Asp Ala Lys Ser His Lys 210 215 220 Glu Ala Val Lys Asn Tyr Lys Gly Asp Ser Thr Gly Arg Thr Ala Ser 225 230 235 240 Tyr Leu Ser Glu Lys Ser Gly Glu Ile Thr Glu Leu Met Leu Glu Gln 245 250 255 Leu Met Ser Asn Ile Gln Arg Asp Ile Gly Asp Lys Gln Lys Glu Ile 260 265 270 Ser Leu Pro Lys Lys Asp Val Val Lys Lys Tyr Leu Glu Ser Glu Ser 275 280 285 Gly Val Pro Tyr Asp Gln Asn Leu Trp Ser Gln Ala Tyr Arg Asn Ala 290 295 300 Ala Ser Ser Ile Lys Lys Thr Asp Thr Arg Asn Phe Asn Ser Thr Leu 305 310 315 320 Glu Lys Phe Lys Asn Glu Val Glu Leu Arg Gly Leu Leu Ser Glu Gly 325 330 335 Asp Asp Val Glu Ile Leu Arg Ser Lys Phe Phe Ser Ser Glu Phe His 340 345 350 Lys Thr Pro Asp Lys Phe Val Ile Lys Pro Glu His Ile Gly Phe Asn 355 360 365 Asn Lys Tyr Asn Val Val Ala Glu Leu Tyr Lys Leu Lys Ala Glu Ala 370 375 380 Thr Asp Phe Glu Ser Ala Phe Ala Thr Val Lys Asp Glu Phe Glu Glu 385 390 395 400 Lys Gly Ile Lys His Pro Ile Lys Asn Ile Leu Glu Tyr Ile Trp Asn 405 410 415 Asn Glu Val Pro Val Glu Lys Trp Gly Arg Val Ala Arg Phe Asn Gln 420 425 430 Ser Glu Glu Lys Leu Leu Arg Ile Lys Ala Asn Pro Thr Val Glu Cys 435 440 445 Asn Gln Gly Met Thr Phe Gly Asn Ser Ala Met Val Gly Glu Val Leu 450 455 460 Arg Ser Asn Tyr Val Ser Lys Lys Gly Ala Leu Val Ser Gly Glu His 465 470 475 480 Gly Gly Arg Leu Ile Gly Gln Asn Asn Met Ile Trp Leu Glu Met Arg 485 490 495 Leu Leu Asn Lys Gly Lys Trp Glu Thr His His Val Pro Thr His Asn 500 505 510 Met Lys Phe Phe Glu Glu Val His Ala Tyr Asn Pro Ser Leu Ala Asp 515 520 525 Ser Val Asn Val Arg Asn Arg Leu Tyr Arg Ser Glu Asp Tyr Thr Gln 530 535 540 Leu Pro Ser Ser Ile Thr Asp Gly Leu Lys Gly Asn Pro Lys Ala Lys 545 550 555 560 Leu Leu Lys Arg Gln His Cys Ala Leu Asn Asn Met Thr Ala Asn Val 565 570 575 Leu Asn Pro Lys Leu Ser Phe Thr Ile Asn Lys Lys Asn Asp Asp Tyr 580 585 590 Thr Val Ile Ile Val His Ser Val Glu Val Ser Lys Pro Arg Arg Glu 595 600 605 Val Leu Val Gly Asp Tyr Leu Val Gly Met Asp Gln Asn Gln Thr Ala 610 615 620 Ser Asn Thr Tyr Ala Val Met Gln Val Val Lys Pro Lys Ser Thr Asp 625 630 635 640 Ala Ile Pro Phe Arg Asn Met Trp Val Arg Phe Val Glu Ser Gly Ser 645 650 655 Ile Glu Ser Arg Thr Leu Asn Ser Arg Gly Glu Tyr Val Asp Gln Leu 660 665 670 Asn His Asp Gly Val Asp Leu Phe Glu Ile Gly Asp Thr Glu Trp Val 675 680 685 Asp Ser Ala Arg Lys Phe Phe Asn Lys Leu Gly Val Lys His Lys Asp 690 695 700 Gly Thr Leu Val Asp Leu Ser Thr Ala Pro Arg Lys Ala Tyr Ala Phe 705 710 715 720 Asn Asn Phe Tyr Phe Lys Thr Met Leu Asn His Leu Arg Ser Asn Glu 725 730 735 Val Asp Leu Thr Leu Leu Arg Asn Glu Ile Leu Arg Val Ala Asn Gly 740 745 750 Arg Phe Ser Pro Met Arg Leu Gly Ser Leu Ser Trp Thr Thr Leu Lys 755 760 765 Ala Leu Gly Ser Phe Lys Ser Leu Val Leu Ser Tyr Phe Asp Arg Leu 770 775 780 Gly Ala Lys Glu Met Val Asp Lys Glu Ala Lys Asp Lys Ser Leu Phe 785 790 795 800 Asp Leu Leu Val Ala Ile Asn Asn Lys Arg Ser Asn Lys Arg Glu Glu 805 810 815 Arg Thr Ser Arg Ile Ala Ser Ser Leu Met Thr Val Ala Gln Lys Tyr 820 825 830 Lys Val Asp Asn Ala Val Val His Val Val Val Glu Gly Asn Leu Ser 835 840 845 Ser Thr Asp Arg Ser Ala Ser Lys Ala His Asn Arg Asn Thr Met Asp 850 855 860 Trp Cys Ser Arg Ala Val Val Lys Lys Leu Glu Asp Met Cys Asn Leu 865 870 875 880 Tyr Gly Phe Asn Ile Lys Gly Val Pro Ala Phe Tyr Thr Ser His Gln 885 890 895 Asp Pro Leu Val His Arg Ala Asp Tyr Asp Pro Lys Pro Ala Leu 900 905 910 Arg Cys Arg Tyr Ser Ser Tyr Ser Arg Ala Asp Phe Ser Lys Trp Gly 915,920,925 Gln Asn Only Leu Only Only Val Val Arg Only Trp Only Asn Lys On Only 930,935,940 The Asn Thr Cys Tyr Lys Val Gly Ala Val Glu Phe Leu Lys Gln His Gly 945 950 955 960 Leu Phe Ala Asp Lys Lys Leu Thr Val Glu Gln Phe Leu Ser Lys Val 965,970,975 Lys Asp Glu Glu Ile Leu Ile Pro Arg Arg Gly Gly Arg Val Phe Leu 980,985,990 Thr Thr His Arg Leu Leu Ala Glu Served Thr Phe Val Tyr Leu Asn Gly 995 1000 1005 Val Lys Tyr His Ser Cys Asn Ala Asp Glu Val Ala Ala Val Asn 1010 1015 1020 Ile Cys Leu Asn Asp Trp Val Ile Pro Cys Lys Lys Met Lys 1025 1030 1035 Glu Glu Ser Ser Ala Ser Gly 1040 1045 <210> 2 <211> 908 <212> PRT <213> Artificial Sequence <220> <223> Cas12j <400> 2 Met Pro Ser Tyr Lys Ser Ser Arg Val Leu Val Arg Asp Val Pro Glu 1 5 10 15 Glu Leu Val Asp His Tyr Glu Arg Ser His Arg Val Ala Ala Phe Phe 20 25 30 Met Arg Leu Leu Leu Ala Met Arg Arg Glu Pro Tyr Ser Leu Arg Met 35 40 45 Arg Asp Gly Thr Glu Arg Glu Val Asp Leu Asp Glu Thr Asp Asp Phe 50 55 60 Leu Arg Ser Ala Gly Cys Glu Glu Pro Asp Ala Val Ser Asp Asp Leu 65 70 75 80 Arg Ser Phe Ala Leu Ala Val Leu His Gln Asp Asn Pro Lys Lys Arg 85 90 95 Ala Phe Leu Glu Ser Glu Asn Cys Val Ser Ile Leu Cys Leu Glu Lys 100 105 110 Ser Ala Ser Gly Thr Arg Tyr Tyr Lys Arg Pro Gly Tyr Gln Leu Leu 115 120 125 Lys Lys Ala Ile Glu Glu Glu Trp Gly Trp Asp Lys Phe Glu Ala Ser 130 135 140 Leu Leu Asp Glu Arg Thr Gly Glu Val Ala Glu Lys Phe Ala Ala Leu 145 150 155 160 Ser Met Glu Asp Trp Arg Arg Phe Phe Ala Ala Arg Asp Pro Asp Asp 165 170 175 Leu Gly Arg Glu Leu Leu Lys Thr Asp Thr Arg Glu Gly Met Ala Ala 180 185 190 Ala Leu Arg Leu Arg Glu Arg Gly Val Phe Pro Val Ser Val Pro Glu 195 200 205 His Leu Asp Leu Asp Ser Leu Lys Ala Ala Met Ala Ser Ala Ala Glu 210 215 220 Arg Leu Lys Ser Trp Leu Ala Cys Asn Gln Arg Ala Val Asp Glu Lys 225 230 235 240 Ser Glu Leu Arg Lys Arg Phe Glu Glu Ala Leu Asp Gly Val Asp Pro 245 250 255 Glu Lys Tyr Ala Leu Phe Glu Lys Phe Ala Ala Glu Leu Gln Gln Ala 260 265 270 Asp Tyr Asn Val Thr Lys Lys Leu Val Leu Ala Val Ser Ala Lys Phe 275 280 285 Pro Ala Thr Glu Pro Ser Glu Phe Lys Arg Gly Val Glu Ile Leu Lys 290 295 300 Glu Asp Gly Tyr Lys Pro Leu Trp Glu Asp Phe Arg Glu Leu Gly Phe 305 310 315 320 Val Tyr Leu Ala Glu Arg Lys Trp Glu Arg Arg Arg Gly Gly Ala Ala 325 330 335 Val Thr Leu Cys Asp Ala Asp Asp Ser Pro Ile Lys Val Arg Phe Gly 340 345 350 Leu Thr Gly Arg Gly Arg Lys Phe Val Leu Ser Ala Ala Gly Ser Arg 355 360 365 Phe Leu Ile Thr Val Lys Leu Pro Cys Gly Asp Val Gly Leu Thr Ala 370 375 380 Val Pro Ser Arg Tyr Phe Trp Asn Pro Ser Val Gly Arg Thr Thr Ser 385 390 395 400 Asn Ser Phe Arg Ile Glu Phe Thr Lys Arg Thr Thr Glu Asn Arg Arg 405 410 415 Tyr Val Gly Glu Val Lys Glu Ile Gly Leu Val Arg Gln Arg Gly Arg 420 425 430 Tyr Tyr Phe Phe Ile Asp Tyr Asn Phe Asp Pro Glu Glu Val Ser Asp 435 440 445 Glu Thr Lys Val Gly Arg Ala Phe Phe Arg Ala Pro Leu Asn Glu Ser 450 455 460 Arg Pro Lys Pro Lys Asp Lys Leu Thr Val Met Gly Ile Asp Leu Gly 465 470 475 480 Ile Asn Pro Ala Phe Ala Phe Ala Val Cys Thr Leu Gly Glu Cys Gln 485 490 495 Asp Gly Ile Arg Ser Pro Val Ala Lys Met Glu Asp Val Ser Phe Asp 500 505 510 Ser Thr Gly Leu Arg Gly Gly Ile Gly Ser Gln Lys Leu His Arg Glu 515 520 525 Met His Asn Leu Ser Asp Arg Cys Phe Tyr Gly Ala Arg Tyr Ile Arg 530 535 540 Leu Ser Lys Lys Leu Arg Asp Arg Gly Ala Leu Asn Asp Ile Glu Ala 545 550 555 560 Arg Leu Leu Glu Glu Lys Tyr Ile Pro Gly Phe Arg Ile Val His Ile 565 570 575 Glu Asp Ala Asp Glu Arg Arg Arg Thr Val Gly Arg Thr Val Lys Glu 580 585 590 Ile Lys Gln Glu Tyr Lys Arg Ile Arg His Gln Phe Tyr Leu Arg Tyr 595 600 605 His Thr Ser Lys Arg Asp Arg Thr Glu Leu Ile Ser Ala Glu Tyr Phe 610 615 620 Arg Met Leu Phe Leu Val Lys Asn Leu Arg Asn Leu Leu Lys Ser Trp 625 630 635 640 Asn Arg Tyr His Trp Thr Thr Gly Asp Arg Glu Arg Arg Gly Gly Asn 645 650 655 Pro Asp Glu Leu Lys Ser Tyr Val Arg Tyr Tyr Asn Asn Leu Arg Met 660 665 670 Asp Thr Leu Lys Lys Leu Thr Cys Ala Ile Val Arg Thr Ala Lys Glu 675 680 685 His Gly Ala Thr Leu Val Ala Met Glu Asn Ile Gln Arg Val Asp Arg 690 695 700 Asp Asp Glu Val Lys Arg Arg Lys Glu Asn Ser Leu Leu Ser Leu Trp 705 710 715 720 Ala Pro Gly Met Val Leu Glu Arg Val Glu Gln Glu Leu Lys Asn Glu 725 730 735 Gly Ile Leu Ala Trp Glu Val Asp Pro Arg His Thr Ser Gln Thr Ser 740 745 750 Cys Ile Thr Asp Glu Phe Gly Tyr Arg Ser Leu Val Ala Lys Asp Thr 755 760 765 Phe Tyr Phe Glu Gln Asp Arg Lys Ile His Arg Ile Asp Ala Asp Val 770 775 780 Asn Ala Ala Ile Asn Ile Ala Arg Arg Phe Leu Thr Arg Tyr Arg Ser 785 790 795 800 Leu Thr Gln Leu Trp Ala Ser Leu Leu Asp Asp Gly Arg Tyr Leu Val 805 810 815 Asn Val Thr Arg Gln His Glu Arg Ala Tyr Leu Glu Leu Gln Thr Gly 820 825 830 Ala Pro Ala Ala Thr Leu Asn Pro Thr Ala Glu Ala Ser Tyr Glu Leu 835 840 845 Val Gly Leu Ser Pro Glu Glu Glu Glu Leu Ala Gln Thr Arg Ile Lys 850 855 860 Arg Lys Lys Arg Glu Pro Phe Tyr Arg His Glu Gly Val Trp Leu Thr 865 870 875 880 Arg Glu Lys His Arg Glu Gln Val His Glu Leu Arg Asn Gln Val Leu 885 890 895 Ala Leu Gly Asn Ala Lys Ile Pro Glu Ile Arg Thr 900 905 <210> 3 <211> 1228 <212> PRT <213> Artificial Sequence <220> <223> LbCas12a <400> 3 Met Lys Ser Leu Glu Lys Phe Thr Asn Cys Tyr Ser Leu Ser Leu Ser Leu Lys Thr 1 5 10 15 Leu Arg Phe Lys Ala Ile Pro Val Gly Lys Thr Gln Glu Asn Ile Asp 20 25 30 Asn Lys Arg Leu Leu Val Glu Asp Glu Lys Arg Ala Glu Asp Tyr Lys 35 40 45 Gly Val Lys Lys Leu Asp Arg Tyr Tyr Leu Served Phe Ile Asn Asp 50 55 60 Val Leu His Ser Ile Lys Lys Asn Leu Asn Asn Tyr Ile Ser Leu 65 70 75 80 Phe Arg Lys Thr Arg Thr Glu Lys Glu Asn Lys Glu Leu Glu Asn 85 90 95 Leu Glu Ile Asn Leu Arg Lys Glu Ile Ala Lys Ala Phe Lys Gly Asn 100 105 110 Glu Gly Tyr Lys Ser Leu Phe Lys Asp Ile Glu Thr Ile Leu 115 120 125 Pro Glu Phe Leu Asp Asp Lys Asp Glu Ile Ala Leu Val Asn Ser Phe 130 135 140 Asn Gly Phe Thr Thr Ala Phe Thr Gly Phe Phe Asp Asn Arg Glu Asn 145 150 155 160 Met Phe Ser Glu Glu Ala Lys Ser Thr Ser Ile Ala Phe Arg Cys Ile 165 170 175 Asn Glu Asn Leu Thr Arg Tyr Ile Ser Asn Met Asp Ile Phe Glu Lys 180 185 190 Val Asp Ala Ile Phe Asp Lys His Glu Val Gln Glu Ile Lys Glu Lys 195 200 205 Ile Leu Asn Ser Asp Tyr Asp Val Glu Asp Phe Phe Glu Gly Glu Phe 210 215 220 Phe Asn Phe Val Leu Thr Gln Glu Gly Ile Asp Val Tyr Asn Ala Ile 225 230 235 240 Ile Gly Gly Phe Val Thr Glu Ser Gly Glu Lys Ile Lys Gly Leu Asn 245 250 255 Glu Tyr Ile Asn Leu Tyr Asn Gln Lys Thr Lys Gln Lys Leu Pro Lys 260 265 270 Phe Lys Pro Leu Tyr Lys Gln Val Leu Ser Asp Arg Glu Ser Leu Ser 275 280 285 Phe Tyr Gly Glu Gly Tyr Thr Ser Asp Glu Glu Val Leu Glu Val Phe 290 295 300 Arg Asn Thr Leu Asn Lys Asn Ser Glu Ile Phe Ser Ser Ile Lys Lys 305 310 315 320 Leu Glu Lys Leu Phe Lys Asn Phe Asp Glu Tyr Ser Ser Ala Gly Ile 325 330 335 Phe Val Lys Asn Gly Pro Ala Ile Ser Thr Ile Ser Lys Asp Ile Phe 340 345 350 Gly Glu Trp Asn Val Ile Arg Asp Lys Trp Asn Ala Glu Tyr Asp Asp 355 360 365 Ile His Leu Lys Lys Lys Ala Val Val Thr Glu Lys Tyr Glu Asp Asp 370 375 380 Arg Arg Lys Ser Phe Lys Lys Ile Gly Ser Phe Ser Leu Glu Gln Leu 385 390 395 400 Gln Glu Tyr Ala Asp Ala Asp Leu Ser Val Val Glu Lys Leu Lys Glu 405 410 415 Ile Ile Ile Gln Lys Val Asp Glu Ile Tyr Lys Val Tyr Gly Ser Ser 420 425 430 Glu Lys Leu Phe Asp Ala Asp Phe Val Leu Glu Lys Ser Leu Lys Lys 435 440 445 Asn Asp Ala Val Val Ala Ile Met Lys Asp Leu Leu Asp Ser Val Lys 450 455 460 Ser Phe Glu Asn Tyr Ile Lys Ala Phe Phe Gly Glu Gly Lys Glu Thr 465 470 475 480 Asn Arg Asp Glu Ser Phe Tyr Gly Asp Phe Val Leu Ala Tyr Asp Ile 485,490,495 Leu Leu Lys Val Asp His With Tyr Asp With Arg Asn Tyr Val Thr 500 505 510 Gln Lys Pro Tyr Ser Lys Asp Lys Phe Lys Leu Tyr Phe Gln Asn Pro 515,520,525 Gln Phe Met Gly Gly Trp Asp Lys Asp Lys Glu Thr Asp Tyr Arg Ala 530 535 540 Thr Ile Leu Arg Tyr Gly Ser Lys Tyr Leu Ala Ile Met Asp Lys 545 550 555 560 Lys Tyr Ala Lys Cys Leu Gln Lys Ile Asp Lys Asp Val Asn Gly 565,570,575 Asn Tyr Glu Lys And Asn Tyr Lys Leu Pro Gly Pro Asn Lys Met 580,585,590 Leu Pro Lys Val Phe Phe Ser Lys Lys Trp Met Ala Tyr Tyr Asn Pro 595,600,605 Serving Glu Asp With Gln Lys Ile Tyr Lys Asn Gly Thr Phe Lys Gly 610 615 620 Asp Met Phe Asn Leu Asn Asp Cys His Lys Leu Ile Asp Phe Phe Lys 625 630 635 640 Asp Ser Ile Ser Arg Tyr Pro Lys Trp Ser Asn Ala Tyr Asp Phe Asn 645,650,655 Phe Ser Glu Thr Glu Lys Tyr Lys Asp Ile Ala Gly Phe Tyr Arg Glu 660,665,670 Val Glu Glu Gln Gly Tyr Lys Val Ser Phe Glu Ser Ala Ser Lys Lys 675,680,685 Glu Val Asp Lys Leu Val Glu Glu Gly Lys Leu Tyr Met Phe Gln Ile 690,695,700 Tyr Asn Lys Asp Phe Ser Asp Lys Ser His Gly Thr Pro Asn Leu His 705 710 715 720 Thr Met Tyr Phe Lys Leu Leu Phe Asp Glu Asn Asn His Gly Gln Ile 725 730 735 Arg Leu Serving Gly Gly Ala Glu Leu Phe Met Arg Arg Serving Lys 740,745,750 Lys Glu Glu Leu Val Val His Pro Ala Asn Ser Pro Ile Ala Asn Lys 755,760,765 Asn Pro Asp Asn Pro Lys Lys Thr Thr Thr Leu Ser Tyr Asp Val Tyr 770 775 780 Lys Asp Lys Arg Phe Ser Glu Asp Gln Tyr Glu Leu His Ile Pro Ile 785 790 795 800 Ala Ile Asn Lys Cys Pro Lys Asn Ile Phe Lys Ile Asn Thr Glu Val 805 810 815 Arg Val Leu Leu Lys His Asp Asp Asn Pro Tyr Val Ile Gly Ile Asp 820 825 830 Arg Gly Glu Arg Asn Leu Leu Tyr Ile Val Val Val Asp Gly Lys Gly 835 840 845 Asn Ile Val Glu Gln Tyr Ser Leu Asn Glu Ile Ile Asn Asn Phe Asn 850 855 860 Gly Ile Arg Ile Lys Thr Asp Tyr His Ser Leu Leu Asp Lys Lys Glu 865 870 875 880 Lys Glu Arg Phe Glu Ala Arg Gln Asn Trp Thr Ser Ile Glu Asn Ile 885 890 895 Lys Glu Leu Lys Ala Gly Tyr Ile Ser Gln Val Val His Lys Ile Cys 900 905 910 Glu Leu Val Glu Lys Tyr Asp Ala Val Ile Ala Leu Glu Asp Leu Asn 915 920 925 Gly Phe Lys Asn Ser Arg Val Lys Val Glu Lys Gln Val Tyr Gln 930,935,940 Lys Phe Glu Lys Met Leu Ile Asp Lys Leu Asn Tyr Met Val Asp Lys 945 950 955 960 Lys Ser Asn Pro Cys Ala Thr Gly Gly Ala Leu Lys Gly Tyr Gln Ile 965,970,975 Thr Asn Lys Phe Glu Ser Phe Lys Ser Met Ser Gln Asn Gly Phe 980,985,990 Ile Phe Tyr Ile Pro Ala Trp Leu Thr Ser Lys Ile Asp Pro Ser Thr 995 1000 1005 Gly Phe Val Asn Leu Leu Lys Thr Lys Tyr Thr Ser Ile Ala Asp 1010 1015 1020 Ser Lys Lys Phe Ile Ser Phe Asp Arg Ile Met Tyr Val Pro 1025 1030 1035 Glu Glu Asp Leu Phe Glu Phe Ala Leu Asp Tyr Lys Asn Phe Ser 1040 1045 1050 Arg Thr Asp Ala Asp Tyr Ile Lys Trp Lys Leu Tyr Ser Tyr 1055 1060 1065 Gly Asn Arg Ile Arg Ile Phe Arg Asn Pro Lys Lys Asn Asn Val 1070 1075 1080 Phe Asp Trp Glu Glu Val Cys Leu Thr Ser Ala Tyr Lys Glu Leu 1085 1090 1095 Phe Asn Lys Tyr Gly Ile Asn Tyr Gln Gln Gly Asp Ile Arg Ala 1100 1105 1110 Leu Leu Cys Glu Gln Ser Asp Lys Ala Phe Tyr Ser Ser Phe Met 1115 1120 1125 Ala Leu Met Ser Leu Met Leu Gln Met Arg Asn Ser Ile Thr Gly 1130 1135 1140 Arg Thr Asp Val Asp Phe Leu Ile Ser Pro Val Lys Asn Ser Asp 1145 1150 1155 Gly Ile Phe Tyr Asp Ser Arg Asn Tyr Glu Ala Gln Glu Asn Ala 1160 1165 1170 Ile Leu Pro Lys Asn Ala Asp Ala Asn Gly Ala Tyr Asn Ile Ala 1175 1180 1185 Arg Lys Val Leu Trp Ala Ile Gly Gln Phe Lys Lys Ala Glu Asp 1190 1195 1200 Glu Lys Leu Asp Lys Val Lys Ile Ala Ile Ser Asn Lys Glu Trp 1205 1210 1215 Leu Glu Tyr Ala Gln Thr Ser Val Lys His 1220 1225 <210> 4 <211> 1129 <212> PRT <213> Artificial Sequence <220> <223> Cas12b <400> 4 Met Ala Val Lys Ser Ile Lys Val Lys Leu Arg Leu Asp Asp Met Pro 1 5 10 15 Glu Ile Arg Ala Gly Leu Trp Lys Leu His Lys Glu Val Asn Ala Gly 20 25 30 Val Arg Tyr Tyr Thr Glu Trp Leu Ser Leu Leu Arg Gln Glu Asn Leu 35 40 45 Tyr Arg Arg Ser Pro Asn Gly Asp Gly Glu Gln Glu Cys Asp Lys Thr 50 55 60 Ala Glu Glu Cys Lys Ala Glu Leu Leu Glu Arg Leu Arg Ala Arg Gln 65 70 75 80 Val Glu Asn Gly His Arg Gly Pro Ala Gly Ser Asp Asp Glu Leu Leu 85 90 95 Gln Leu Ala Arg Gln Leu Tyr Glu Leu Leu Val Pro Gln Ala Ile Gly 100 105 110 Ala Lys Gly Asp Ala Gln Gln Ile Ala Arg Lys Phe Leu Ser Pro Leu 115 120 125 Ala Asp Lys Asp Ala Val Gly Gly Leu Gly Ile Ala Lys Ala Gly Asn 130 135 140 Lys Pro Arg Trp Val Arg Met Arg Glu Ala Gly Glu Pro Gly Trp Glu 145 150 155 160 Glu Glu Lys Glu Lys Ala Glu Thr Arg Lys Ser Ala Asp Arg Thr Ala 165 170 175 Asp Val Leu Arg Ala Leu Ala Asp Phe Gly Leu Lys Pro Leu Met Arg 180 185 190 Val Tyr Thr Asp Ser Glu Met Ser Ser Val Glu Trp Lys Pro Leu Arg 195 200 205 Lys Gly Gln Ala Val Arg Thr Trp Asp Arg Asp Met Phe Gln Gln Ala 210 215 220 Ile Glu Arg Met Met Ser Trp Glu Ser Trp Asn Gln Arg Val Gly Gln 225 230 235 240 Glu Tyr Ala Lys Leu Val Glu Gln Lys Asn Arg Phe Glu Gln Lys Asn 245 250 255 Phe Val Gly Gln Glu His Leu Val His Leu Val Asn Gln Leu Gln Gln 260 265 270 Asp Met Lys Glu Ala Ser Pro Gly Leu Glu Ser Lys Glu Gln Thr Ala 275 280 285 His Tyr Val Thr Gly Arg Ala Leu Arg Gly Ser Asp Lys Val Phe Glu 290 295 300 Lys Trp Gly Lys Leu Ala Pro Asp Ala Pro Phe Asp Leu Tyr Asp Ala 305 310 315 320 Glu Ile Lys Asn Val Gln Arg Arg Asn Thr Arg Arg Phe Gly Ser His 325 330 335 Asp Leu Phe Ala Lys Leu Ala Glu Pro Glu Tyr Gln Ala Leu Trp Arg 340 345 350 Glu Asp Ala Ser Phe Leu Thr Arg Tyr Ala Val Tyr Asn Ser Ile Leu 355 360 365 Arg Lys Leu Asn His Ala Lys Met Phe Ala Thr Phe Thr Leu Pro Asp 370 375 380 Ala Thr Ala His Pro Ile Trp Thr Arg Phe Asp Lys Leu Gly Gly Asn 385 390 395 400 Leu His Gln Tyr Thr Phe Leu Phe Asn Glu Phe Gly Glu Arg Arg His 405 410 415 Ala Ile Arg Phe His Lys Leu Leu Lys Val Glu Asn Gly Val Ala Arg 420 425 430 Glu Val Asp Asp Val Thr Val Pro Ile Ser Met Ser Glu Gln Leu Asp 435 440 445 Asn Leu Leu Pro Arg Asp Pro Asn Glu Pro Ile Ala Leu Tyr Phe Arg 450 455 460 Asp Tyr Gly Ala Glu Gln His Phe Thr Gly Glu Phe Gly Gly Ala Lys 465 470 475 480 Ile Gln Cys Arg Arg Asp Gln Leu Ala His Met His Arg Arg Arg Gly 485 490 495 Ala Arg Asp Val Tyr Leu Asn Val Ser Val Arg Val Gln Ser Gln Ser 500 505 510 Glu Ala Arg Gly Glu Arg Arg Pro Pro Tyr Ala Ala Val Phe Arg Leu 515 520 525 Val Gly Asp Asn His Arg Ala Phe Val His Phe Asp Lys Leu Ser Asp 530 535 540 Tyr Leu Ala Glu His Pro Asp Asp Gly Lys Leu Gly Ser Glu Gly Leu 545 550 555 560 Leu Ser Gly Leu Arg Val Met Ser Val Asp Leu Gly Leu Arg Thr Ser 565 570 575 Ala Ser Ile Ser Val Phe Arg Val Ala Arg Lys Asp Glu Leu Lys Pro 580 585 590 Asn Ser Lys Gly Arg Val Pro Phe Phe Phe Pro Ile Lys Gly Asn Asp 595 600 605 Asn Leu Val Ala Val His Glu Arg Ser Gln Leu Leu Lys Leu Pro Gly 610 615 620 Glu Thr Glu Ser Lys Asp Leu Arg Ala Ile Arg Glu Glu Arg Gln Arg 625 630 635 640 Thr Leu Arg Gln Leu Arg Thr Gln Leu Ala Tyr Leu Arg Leu Leu Val 645 650 655 Arg Cys Gly Ser Glu Asp Val Gly Arg Arg Glu Arg Ser Trp Ala Lys 660 665 670 Leu Ile Glu Gln Pro Val Asp Ala Ala Asn His Met Thr Pro Asp Trp 675 680 685 Arg Glu Ala Phe Glu Asn Glu Leu Gln Lys Leu Lys Ser Leu His Gly 690 695 700 Ile Cys Ser Asp Lys Glu Trp Met Asp Ala Val Tyr Glu Ser Val Arg 705 710 715 720 Arg Val Trp Arg His Met Gly Lys Gln Val Arg Asp Trp Arg Lys Asp 725 730 735 Val Arg Ser Gly Glu Arg Pro Lys Ile Arg Gly Tyr Ala Lys Asp Val 740 745 750 Val Gly Gly Asn Ser Ile Glu Gln Ile Glu Tyr Leu Glu Arg Gln Tyr 755 760 765 Lys Phe Leu Lys Ser Trp Ser Phe Phe Gly Lys Val Ser Gly Gln Val 770 775 780 Ile Arg Ala Glu Lys Gly Ser Arg Phe Ala Ile Thr Leu Arg Glu His 785 790 795 800 Ile Asp His Ala Lys Glu Asp Arg Leu Lys Lys Leu Ala Asp Arg Ile 805 810 815 Ile Met Glu Ala Leu Gly Tyr Val Tyr Ala Leu Asp Glu Arg Gly Lys 820 825 830 Gly Lys Trp Val Ala Lys Tyr Pro Pro Cys Gln Leu Ile Leu Leu Glu 835 840 845 Glu Leu Ser Glu Tyr Gln Phe Asn Asn Asp Arg Pro Pro Ser Glu Asn 850 855 860 Asn Gln Leu Met Gln Trp Ser His Arg Gly Val Phe Gln Glu Leu Ile 865 870 875 880 Asn Gln Ala Gln Val His Asp Leu Leu Val Gly Thr Met Tyr Ala Ala 885 890 895 Phe Ser Ser Arg Phe Asp Ala Arg Thr Gly Ala Pro Gly Ile Arg Cys 900 905 910 Arg Arg Val Pro Ala Arg Cys Thr Gln Glu His Asn Pro Glu Pro Phe 915 920 925 Pro Trp Trp Leu Asn Lys Phe Val Val Glu His Thr Leu Asp Ala Cys 930 935 940 Pro Leu Arg Ala Asp Asp Leu Ile Pro Thr Gly Glu Gly Glu Ile Phe 945 950 955 960 Val Ser Pro Phe Ser Ala Glu Glu Gly Asp Phe His Gln Ile His Ala 965 970 975 Asp Leu Asn Ala Ala Gln Asn Leu Gln Gln Arg Leu Trp Ser Asp Phe 980 985 990 Asp Ile Ser Gln Ile Arg Leu Arg Cys Asp Trp Gly Glu Val Asp Gly 995 1000 1005 Glu Leu Val Leu Ile Pro Arg Leu Thr Gly Lys Arg Thr Ala Asp 1010 1015 1020 Ser Tyr Ser Asn Lys Val Phe Tyr Thr Asn Thr Gly Val Thr Tyr 1025 1030 1035 Tyr Glu Arg Glu Arg Gly Lys Lys Arg Arg Lys Val Phe Ala Gln 1040 1045 1050 Glu Lys Leu Ser Glu Glu Glu Ala Glu Leu Leu Val Glu Ala Asp 1055 1060 1065 Glu Ala Arg Glu Lys Ser Val Val Leu Met Arg Asp Pro Ser Gly 1070 1075 1080 Ile Ile Asn Arg Gly Asn Trp Thr Arg Gln Lys Glu Phe Trp Ser 1085 1090 1095 Met Val Asn Gln Arg Ile Glu Gly Tyr Leu Val Lys Gln Ile Arg 1100 1105 1110 Ser Arg Val Pro Leu Gln Asp Ser Ala Cys Glu Asn Thr Gly Asp 1115 1120 1125 Ile <210> 5 <211> 10 <212> DNA <213> Artificial Sequence <220> <223> Reporter 10 <400> 5 ttgtttgcgt 10 <210> 6 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> Reporter 15 <400> 6 ttgtttgcgt ttgtt 15 <210> 7 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Reporter 20 <400> 7 ttgtttgcgt ttgttttatt 20 <210> 8 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Reporter 25 <400> 8 ttgtttgcgt ttgtttgcgt ttgtt 25 <210> 9 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> Reporter 36 <400> 9 acatgcgctt tgatgcagag ttcacttttg ttgcgt 36 BRIEF DESCRIPTION OF THE DRAWINGS

[0113] Figure 1 .When the target nucleic acid is single-stranded DNA, the fluorescence signal of Cas12i (Cas12i3) at different single-stranded nucleic acid detector lengths.

[0114] Figure 2 .When the target nucleic acid is single-stranded DNA, the fluorescence signal of Cas12j (Cas12j19) at different single-stranded nucleic acid detector lengths.

[0115] Figure 3 .When the target nucleic acid is double-stranded DNA, the detection signals of Cas12i and Cas12j in the case of 5bp and 25bp single-stranded nucleic acid detectors.

[0116] Implementation

[0117] The present invention is further described below in conjunction with the embodiments. The following description is only a preferred embodiment of the present invention, and does not limit the present invention in other forms. Any technician familiar with the profession may use the above disclosed technical content to change it into an equivalent embodiment with equivalent changes. Any simple modification or equivalent change made to the following embodiments based on the technical essence of the present invention without departing from the content of the present invention falls within the protection scope of the present invention.

[0118] The technical solution of the present invention is based on the following principles: the nucleic acid of the sample to be tested is obtained. For example, the target nucleic acid can be obtained by an amplification method, and the gRNA that can be paired with the target nucleic acid is used to guide the Cas protein to recognize and bind to the target nucleic acid; then, the Cas protein stimulates the cutting activity of the single-stranded nucleic acid detector, thereby cutting the single-stranded nucleic acid detector in the system; a fluorescent group and a quenching group are respectively set at both ends of the single-stranded nucleic acid detector, and if the single-stranded nucleic acid detector is cut, fluorescence will be stimulated; if the single-stranded nucleic acid detector cannot be cut, fluorescence will not be stimulated; in other embodiments, the two ends of the single-stranded nucleic acid detector can also be set as a mark that can be detected by colloidal gold.

[0119] Example 1: When the target nucleic acid is single-stranded DNA, testing the effects of single-stranded nucleic acid detectors of different lengths on different Cas effector proteins Effect of Trans

[0120] Single-stranded nucleic acid detectors of different lengths were designed and synthesized. The detailed sequences are shown in Table 1.

[0121] Table 1. Sequences of single-stranded nucleic acid detectors used in the present invention

[0122] name Length (nt) ssDNA detector sequence SEQ ID No. Reporter-TGT 5 ttctt - Reporter 10 10 ttgtttgcgt 5 Reporter 15 15 ttgtttgcgtttgtt 6 Reporter 20 20 ttgtttgcgtttgttttatt 7 Reporter 25 25 ttgtttgcgtttgtttgcgtttgtt 8 Reporter 36 36 acatgcgctttgatgcagagttcacttttgttgcgt 9

[0123] The applicant verified the above two different Cas effector proteins using single-stranded nucleic acid detectors Reporter-TGT, Reporter 10, Reporter 15, Reporter 20, Reporter 25, and Reporter 36 for Cas12i (SEQ ID No. 1) (in the invention, Cas12i3 is sometimes referred to as Cas12i) and Cas12j (SEQ ID No. 2) (in the invention, Cas12j19 is sometimes referred to as Cas12j), and the design is as follows:

[0124] Table 2. Target nucleic acids, gRNAs and single-stranded nucleic acid detectors corresponding to different Cas proteins

[0125]

[0126] The sequence of the target nucleic acid EV71ssDNA is: GTGCACGCAACAAAAGTGAACTCTGCATCAAAGCGCATGT

[0127] The gRNA sequence of i3-1 is: AGAGAAUGUGUGCAUAGUCACAC AUGCAGAGUUCACUUUUGUUGCGU (The underlined sequence is the guide sequence)

[0128] The gRNA sequence of the j19-1 above is: GUGCUGCUGUCUCCCAGACGGGAGGCAGAACUGCAC CAGAGUUCAC UUUUGUUGCGUGCA (underlined is the guide sequence)

[0129] According to the design in Table 2, 20 μl of reaction system was mixed. A negative control (NTC) without target nucleic acid was set up for each reaction to prove that the fluorescence signal was indeed generated by the detection of target nucleic acid. The content of each component in the system is shown in Table 3. The mixed reaction system was reacted at 37°C for 30 minutes, and the fluorescence signal was detected. The results are shown in Figure 1 and Figure 2 shown.

[0130] Table 3. Content of each component in 20μl system

[0131]

[0132] like Figure 1 As shown, Cas12i (Cas12i3) can detect fluorescence signals at different single-stranded nucleic acid detector lengths, among which the single-stranded nucleic acid detector with a length of 25bp is the best.

[0133] like Figure 2 As shown, Cas12j (Cas12j19) can detect fluorescence signals at different single-stranded nucleic acid detector lengths, among which the single-stranded nucleic acid detector with a length of 25bp is the best.

[0134] Example 2: When the target nucleic acid is double-stranded DNA, single-stranded nucleic acid detectors of different lengths are effective for Cas12i and Cas12j. Effects of Trans on the activity of the protein

[0135] Design LAMP primers to amplify target nucleic acid sequences:

[0136] The sequence of the target nucleic acid is: gcgtaggaaggtggagctattcacttacatgcgctttgatgcagagttcacttttgttgcgtgcacacccaccggggaagttgttccacaattgctcc aatatatgtttgtgccacctggagcccctaagccagattcaagggaatcccttgcatggcaaactgccactaacccctcagttttgtcaagctgtcagaccctccag,

[0137] The primer sequences for LAMP amplification are:

[0138] ·VP1-FIP caacttccccggtgggtgtgacttacatgcgctttgatgc

[0139] ·VP1-BIP tgtttgtgccacctggagccaactgaggggttagtggca

[0140] ·VP1-F3caggttacgcgcaaatgc

[0141] ·VP1-B3gggtctgacagcttgacaaa

[0142] ·VP1-LF caacaaaagtgaactct

[0143] ·VP1-LBgggaatcccttgcatggcaaac

[0144] The experiment was designed to compare the effects of gRNA i3-1, gRNA j19-1, Reporter5 and Reporter25, which were consistent with those in Example 1, and Cas12i and Cas12j when performing nucleic acid detection using single-stranded nucleic acid detectors of different lengths when double-stranded DNA was used as the reaction substrate.

[0145] The mixed samples were verified according to the 20 μl reaction system in Example 1. The Cas protein and the corresponding target nucleic acid, gRNA and single-stranded nucleic acid detector in each reaction system are shown in Table 4. The mixed reaction system was reacted at 37° C. for 60 min, and the fluorescence signal was collected every 1 min.

[0146] Table 4. Target nucleic acids, gRNAs and single-stranded nucleic acid detectors corresponding to different Cas proteins

[0147] Cas proteins Target nucleic acid gRNA Name of single-stranded nucleic acid detector Cas12i EV71 i3-1 Reporter5,Reporter25 Cas12j EV71 j19-1 Reporter5,Reporter25

[0148] like Figure 3 As shown, when the single-stranded nucleic acid detector is 25bp, both Cas12i and Cas12j can detect higher fluorescence signals compared to when the single-stranded nucleic acid detector is 5bp.

[0149] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A method for detecting a target nucleic acid in a sample, the method being a method for non-disease diagnosis and treatment purposes, the method comprising contacting the sample with a V-type CRISPR / CAS effector protein, a gRNA and a single-stranded nucleic acid detector, the gRNA comprising a region binding to the CRISPR / CAS effector protein and a guide sequence hybridizing with the target nucleic acid, the V-type CRISPR / CAS effector protein being selected from one of Cas12i and Cas12j; detecting a detectable signal generated by cleavage of the single-stranded nucleic acid detector by the CRISPR / CAS effector protein, thereby detecting the target nucleic acid; The sequence of the single-stranded nucleic acid detector is 25 arbitrary bases; the single-stranded nucleic acid detector does not hybridize with the gRNA; The amino acid sequence of the Cas12i is shown in SEQ ID No. 1, and the amino acid sequence of the Cas12j is shown in SEQ ID No.

2.

2. The method according to claim 1, characterized in that The detectable signal is detected by vision-based detection, sensor-based detection, gold nanoparticle-based detection, fluorescence polarization, fluorescence signal-based detection, colloidal phase transition / dispersion, electrochemical detection, and semiconductor-based detection.

3. The method according to any one of claims 1-2, characterized in that: The 5' end and the 3' end of the single-stranded nucleic acid detector are respectively provided with different reporter groups, or different labeling molecules are respectively provided at both ends of the single-stranded nucleic acid detector.

4. A composition for detecting a target nucleic acid in a sample, characterized in that: The composition includes a V-type CRISPR / CAS effector protein, a gRNA and a single-stranded nucleic acid detector; the gRNA includes a region that binds to the CRISPR / CAS effector protein and a guide sequence that hybridizes with a target nucleic acid, the V-type CRISPR / CAS effector protein is selected from one of Cas12i and Cas12j, and the sequence of the single-stranded nucleic acid detector is 25 arbitrary bases; the single-stranded nucleic acid detector does not hybridize with the gRNA; The amino acid sequence of the Cas12i is shown in SEQ ID No. 1, and the amino acid sequence of the Cas12j is shown in SEQ ID No.

2.

5. A kit for detecting a target nucleic acid in a sample, characterized in that: The kit comprises a V-type CRISPR / CAS effector protein, a gRNA and a single-stranded nucleic acid detector, wherein the gRNA comprises a region binding to the CRISPR / CAS effector protein and a guide sequence hybridizing with a target nucleic acid, the V-type CRISPR / CAS effector protein is selected from one of Cas12i and Cas12j, and the sequence of the single-stranded nucleic acid detector is 25 arbitrary bases; the single-stranded nucleic acid detector does not hybridize with the gRNA; The amino acid sequence of the Cas12i is shown in SEQ ID No. 1, and the amino acid sequence of the Cas12j is shown in SEQ ID No.

2.

6. Use of the composition according to claim 4 or the kit according to claim 5 for improving the detection efficiency of nucleic acid detection, wherein the use is for purposes other than disease diagnosis and treatment.

7. Use of the composition according to claim 4 or the kit according to claim 5 in nucleic acid detection, wherein the use is for purposes other than disease diagnosis and treatment.

8. A method for cutting a single-stranded nucleic acid detector, the method being a method for non-disease diagnosis and treatment purposes, characterized in that: The method comprises contacting a single-stranded nucleic acid detector with a target nucleic acid, a V-type CRISPR / CAS effector protein and a gRNA, wherein the gRNA comprises a region that binds to the CRISPR / CAS effector protein and a guide sequence that hybridizes with the target nucleic acid, the V-type CRISPR / CAS effector protein is selected from one of Cas12i and Cas12j, and the sequence of the single-stranded nucleic acid detector is 25 arbitrary bases; the single-stranded nucleic acid detector does not hybridize with the gRNA; The amino acid sequence of the Cas12i is shown in SEQ ID No. 1, and the amino acid sequence of the Cas12j is shown in SEQ ID No. 2.